Kura Oncology President, Chairman, and CEO Troy Edward Wilson purchased approximately 100,000 shares of the company's common stock on August 24, 2026, according to an SEC Form 4 filing. The transaction was valued at $1.2 million, based on a weighted average purchase price of $12.39 per share. Following the purchase, Wilson's total beneficial ownership stands at roughly 1.2 million shares, an increase of 9%, with about 435,000 shares held directly and 779,000 held indirectly through the One Fish Two Fish Revocable Trust and the Lorax Charitable Remainder Unitrust. The insider buy comes as the clinical-stage biopharmaceutical company reports trailing twelve-month revenue of $77.2 million and a net loss of $296.8 million, with a market capitalization of $1.1 billion. Wilson has led the company since its founding in 2015, and the purchase is seen as a bullish signal given that insiders typically buy only when they expect the share price to rise.
Kura Oncology IncCEO's insider purchase of 100,000 shares signals confidence in the company's prospects.
